 SALT LAKE CITY, Sept. 09, 2021 GLOBE NEWSWIRE -- Clene Inc. NASDAQ: CLNN along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat cellular energetic failure, announced the final patient visit has been completed in its Phase 2 RESCUE-ALS study and that trial close-out activities have begun. RESCUE-ALS investigated the efficacy, safety, pharmacokinetics and pharmacodynamics of Clenes lead drug candidate, CNM-Au8, a catalytically-active gold nanocrystal suspension, in patients with early amyotrophic lateral sclerosis ALS. The trial enrolled a total of 45 patients with ALS, with unblinded topline data expected in Q4 2021. 